An interventional study of Aerobic Exercise and resistance training in Chronic Kidney Disease (CKD) and Renal Dysfunction, sponsored by China Institute of Sport Science. Not yet recruiting at 1 site in China. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by China Institute of Sport Science · Not applicable, Interventional, and Treatment
Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.
Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 109th largest by planned enrollment of the 164 interventional ones that give a count, is one of 27 that started in 2026, is one of 44 with no phase, reaches primary completion later than 71 of the 106 other live ones, and was the 244th registered.
3,090 studies on the registry are indexed under Renal Insufficiency, Chronic; 698 are open to participants now.
Browse Renal Insufficiency, Chronic studies →94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Atom Therapeutics Co., Ltd · Sites in China, Australia
Ages 18–75
AstraZeneca · Sites in China, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in China, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Colombia and 5 more countries
Ages 2–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
245 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 39 · Phase 4 38
First in 2000; this study’s year is marked. 27 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 73 across 2,157 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 182 across the 164 interventional studies, 1,350 across the 80 observational. Of the 84 that completed or were terminated, 21 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 245 have an industry lead sponsor. The 10 most frequent:
China Institute of Sport Science is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
China Institute of Sport Science has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
22 of the studies in Renal Insufficiency, Chronic with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07122401Phase 3Shaanxi Micot Pharmaceutical Technology Co., Ltd.Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism | 2026-11-26 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT05349955Shanghai Zhongshan HospitalEffects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community | 2026-11-30 |
| NCT07262333Beijing Continent Pharmaceutical Co, Ltd.A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency | 2026-12-01 |
Add all 22 to your calendar (.ics) → With an account.
Among the 245 studies in Renal Insufficiency, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compares the effects and safety of aerobic, resistance, and combined exercise versus routine health education on renal function, physical function, and quality of life in people with Chronic kidney disease (CKD) over 12 months, while exploring potential mechanisms.
A total of 120 adults with Chronic kidney disease (CKD) stages G1-G4 will participate in this randomized controlled trial to evaluate the effects and safety of different exercise modalities on renal function, physical function, and quality of life, and to explore potential mechanisms related to renal hemodynamics, inflammation, and oxidative stress. Participants will be randomly assigned to aerobic exercise, resistance exercise, combined exercise, or control groups, with 30 participants planned per group. The study will last 12 months, with assessments at baseline and months 2, 4, 6, and 12.\<br> \<br> Participants in the exercise groups will complete three approximately 60-minute sessions weekly, including at least one supervised in-person session and remotely monitored sessions. Aerobic exercise will target 55-80% of estimated maximum heart rate. Resistance exercise will use resistance bands and body weight, with intensity adjusted according to individual ability and perceived exertion. The combined group will perform two aerobic and one resistance session weekly. The control group will receive routine CKD health education without structured exercise training during the study.\<br> \<br> Primary outcomes include renal function and metabolic parameters. Secondary outcomes include physical function, body composition, and quality of life. Exploratory assessments will examine renal hemodynamics, inflammatory markers, oxidative stress, and fibrosis-related biomarkers. Exercise participation and adherence will be monitored, and adverse events will be recorded in all groups. Serious adverse events will be managed according to the study protocol and applicable ethics requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
\<p style="line-height: 2.5;">
Exclusion Criteria:
\<p style="line-height: 2.5;">
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this group will receive aerobic exercise training.
Other: Aerobic Exercise
Participants assigned to this group will receive resistance training.
Other: resistance training
Participants assignedto this group will receive combined aerobic andresistance exercise training.
Other: Combined Exercise
Participants received conventional health education.
Participants will undergo aerobic exercise training three times per week for 12 months, with each session lasting approximately 60 minutes. Training will consist primarily of aerobic movements, including high knees, half-squat jumping jacks, boxing steps, V-steps with arm movements, knee lifts with torso rotation, and jumping jacks. Exercise intensity will be targeted at 55%-80% of age-predicted maximum heart rate calculated using the Tanaka formula. Heart rate and session duration will be monitored using a Huawei fitness band. Exercise intensity and difficulty will be individually adjusted according to exercise tolerance and training performance. Progression may involve increasing exercise duration, movement speed, or exercise difficulty. Sessions will include 3-5 minutes of warm-up and 3-5 minutes of cool-down and stretching.
Participants will undergo progressive resistance training three times per week for 12 months, with each session lasting approximately 60 minutes. Training will primarily use resistance bands and bodyweight exercises, including resistance-band chest presses, resistance-band rows, squats, and other exercises adapted to individual physical capacity. Resistance and exercise difficulty will be selected according to baseline exercise capacity and training experience. The target intensity will be adjusted using the rating of perceived exertion (RPE), with participants performing 10-15 repetitions to a level at which the exercise feels substantially effortful. Training will begin with lower resistance and fewer sets, with progressive increases in resistance or sets according to individual tolerance and performance. Exercise completion, resistance, repetitions, fatigue, and discomfort will be recorded throughout the intervention.
Participants will undergo combined exercise training three times per week for 12 months, with each session lasting approximately 60 minutes. The weekly program will include two aerobic exercise sessions and one resistance exercise session. Aerobic training will use movements such as high knees, half-squat jumping jacks, boxing steps, V-steps with arm movements, knee lifts with torso rotation, and jumping jacks, with intensity targeted at 55%-80% of age-predicted maximum heart rate calculated using the Tanaka formula. Resistance training will use resistance bands and bodyweight exercises, with intensity adjusted according to the rating of perceived exertion (RPE) and individual exercise capacity. Exercise intensity and difficulty will be progressively adjusted according to tolerance and performance. Heart rate, session duration, exercise completion, and training-related discomfort will be monitored and recorded.
Estimated glomerular filtration rate
Estimated glomerular filtration rate will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Renal resistance index
The renal resistance index (RI) will be assessed by qualified physicians using Doppler ultrasonography of the bilateral interlobar arteries. Measurements will be obtained at standardized sampling sites in both kidneys, with a sampling gate of 2-4 mm and a Doppler angle of less than 60°.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Serum creatinine
Serum creatinine will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
The four standard blood lipid parameters
The four standard blood lipid parameters, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), will be measured using blood samples collected from participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
blood glucose
blood glucose will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Urinary protein
Urinary protein levels will be measured using urine samples collected from participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Urinary albumin-to-creatinine ratio
The urinary albumin-to-creatinine ratiowill be measured using urine samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Endogenous Creatinine Clearance
Endogenous creatinine clearance will be measured using urine samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
6-minute walk test
Participants will walk as far as possible at their maximum tolerable pace within 6 minutes, and the total distance walked will be recorded.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
30-second sit-to-stand test
Participants will complete as many sit-to-stand repetitions as possible within 30 seconds, and the total number of completed repetitions will be recorded.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
vital capacity
Vital capacity will be measured using a standardized spirometer.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
grip strength
Handgrip strength will be assessed using a calibrated handgrip dynamometer
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Body fat percentage
Body fat percentage will be measured using an InBody body composition analyzer.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
malondialdehyde
Malondialdehyde will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
superoxide dismutase
Superoxide dismutase will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
glutathione peroxidase
Glutathione peroxidase will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
C-reactive protein
C-reactive protein will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
interleukin-6
interleukin-6 will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
tumor necrosis factor-α
Tumor necrosis factor-α will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Interleukin-10
Interleukin-10 will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Transforming growth factor-β1
Transforming growth factor-β1 will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
connective tissue growth factor
Connective tissue growth factor will be measured using blood samples collected from the participants.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Short Form-36 Health Survey
Short Form-36 Health Survey will be assessed using a questionnaire.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Renal blood flow
Renal blood flow will be assessed by qualified physicians using ultrasonography.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
Peak systolic velocity
Peak systolic velocity will be assessed by qualified physicians using ultrasonography.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
end-diastolic velocity
end-diastolic velocity will be assessed by qualified physicians using ultrasonography.
Time frame: Baseline and at 2, 4, 6, and 12 months after initiation of the intervention
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data will be made available on request.
Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.
Of 576 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 14 months is below that.
Counting every sponsor, half of 616 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
China Institute of Sport Science